Session: MON 167-198-Hypothalamus-Pituitary Development & Biology
Poster Board MON-195
Alin Abreu, MD firstname.lastname@example.org
Rafael Castellanos MDheavenlycouott@hotmail.com
Alejandro Pinzon MD email@example.com
Humberto Franco MD firstname.lastname@example.org
Dinett Movilla, MD email@example.com
1. Endocrinología, Centro Médico Imbanaco, Cali, Valle, Colombia
2. Medicina Interna, Universidad Industrial de Santander. Bucaramanga. Colombia.
3. Endocrinología, Hospital Universitario de Neiva, Neiva, Huila, Colombia
4. Endocrinología, Hospital de Caldas, Manizales, Caldas, Colombia
5. Endocrinología, Coomeva. Barranquilla, Atlántico, Colombia
Acromegaly is a clinical disorder characterized by progressive somatic disfigurement and a wide range of systemic complications mediated by effects of GH and IGF-I hypersecretion. Due to its slow clinical progression, diagnosis is often delayed four to ten years or more, increasing morbidity and mortality due to cardiovascular or respiratory disease, metabolic complications or malignancies. The frequency of these complications in patients with Acromegaly in Colombia is
Purpose: to characterize and determine the frequency of the systemic complications of acromegaly in a sample of patients from Barranquilla, Bucaramanga, Cali, Manizales y Neiva (Colombia).
Methods: Case series. All cases from patients with Acromegaly consulting to referral centers in these cities were retrieved and reviewed. Patients were called in and systematically evaluated to determine the presence of hypertension, carbohydrate intolerance, diabetes, cardiovascular disease, sleep apnea, and intestinal disorders during their visit.
Results: 69 patients were evaluated (55% females, 45% males; with a median age 49,9 (20-81) yrs. At evaluation, the time of disease evolution was 8,12 yrs, (1-27 ys), 73% had macroadenomas, 24% had microadenomas and 1,4 % did not have either of them. The most frequent previous treatment was surgery + medical (45%), followed by medical (25,3%), surgery (19,6%); 10,1% had no treatment.
Mean lab values were IGF-I 832.56±476.86ng/ml; basal GH 18,63±26,93ng/ml; FBG 106,11±27,11mg/dl; prolactin 205,15±1009,67ng/ml.
Clinical complications present: acromegalic cardiopathy 36,5%; diabetes 34,5%; HTN 55%; arrhythmias 19,3%; sleep apnea 19% (severe), 10% (moderate), 12% (mild); adenomatous polyposis 9,6%, hyperplasic polyps 9,0%, colon cancer 1,8% and hip luxation 1,4%.
Ordered treatment after evaluation: medical 36.3%, surgery 15.1%; medical+radiosurgery 13,6%; medical+surgery 19,6 %; surgery+radiosurgery 4,5%; medical+surgery+radiosurgery 10,6 %.
Conclusions: Cardiovascular, metabolic and respiratory complications are frequent among acromegalic patients. The presence of complications in patients with acromegaly should be evaluated at the time of diagnosis y on a regular basis.
Nothing to Disclose: AA, RC, AP, HIF, DM
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters